-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Moderna Income Statement
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue |
|
$274.49 M | $17.74 B | $19.26 B | $6.85 B | $3.24 B |
| Cost of Revenue |
|
$7.93 M | $2.62 B | $5.42 B | $4.69 B | $1.46 B |
| Gross Profit |
|
$266.56 M | $15.12 B | $13.85 B | $2.16 B | $1.77 B |
| Research & Development |
|
$1.37 B | $1.99 B | $3.30 B | $4.85 B | $4.54 B |
| Selling,General & Administrative |
|
$188.27 M | $567.00 M | $1.13 B | $1.55 B | $1.17 B |
| Operating Expense |
|
$1.03 B | $1.82 B | $4.43 B | $6.30 B | $5.72 B |
| Operating Income |
|
-$763.14 M | $13.30 B | $9.42 B | -$4.24 B | -$3.95 B |
| Net Income |
|
-$747.06 M | $12.20 B | $8.36 B | -$4.71 B | -$3.56 B |
Moderna Balance Sheet
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$4.61 B | $10.73 B | $9.90 B | $8.60 B | $1.93 B |
| Inventories |
|
$47.00 M | $1.44 B | $949.00 M | $202.00 M | $117.00 M |
| Total Current Assets |
|
$6.30 B | $16.07 B | $13.43 B | $10.33 B | $8.10 B |
| Property,Plant and Equipment |
|
$387.00 M | $1.38 B | $2.14 B | $2.66 B | $2.96 B |
| Goodwill |
|
- | - | - | $52.00 M | $52.00 M |
| Total Assets |
|
$7.34 B | $24.67 B | $25.86 B | $18.43 B | $14.14 B |
| Total Liabilities |
|
$4.78 B | $10.52 B | $6.74 B | $4.57 B | $3.24 B |
| Retained Earnings |
|
-$2.24 B | $9.96 B | $18.32 B | $13.61 B | $10.05 B |
| Total Shareholder Equity |
|
$2.56 B | $14.15 B | $19.12 B | $13.85 B | $10.90 B |
| Common Stock |
|
- | - | - | - | - |
Moderna Cash flow
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$31.25 M | $232.00 M | $348.00 M | $621.00 M | $189.00 M |
| Dividends Payout |
|
- | - | - | - | - |
| Capital Expenditures (Capex) |
|
-$67.45 M | -$284.00 M | -$400.00 M | -$707.00 M | -$1.05 B |
| Free Cash Flow (FCF) |
|
$1.96 B | $13.34 B | $4.58 B | -$3.83 B | -$4.06 B |
Moderna Profitability
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Gross Profit |
|
$266.56 M | $15.12 B | $13.85 B | $2.16 B | $1.77 B |
| Gross Profit Margin (%) |
|
97.11% | 85.24% | 71.88% | 31.47% | 54.76% |
| Operating Income |
|
-$763.14 M | $13.30 B | $9.42 B | -$4.24 B | -$3.95 B |
| Operating Income Margin (%) |
|
-278.02% | 74.97% | 48.90% | -61.90% | -121.91% |
| Net Income |
|
-$747.06 M | $12.20 B | $8.36 B | -$4.71 B | -$3.56 B |
| Net Income Margin (%) |
|
-272.16% | 68.80% | 43.41% | -68.84% | -110.04% |
| EBITDA |
|
-$732.00 M | $13.53 B | $9.77 B | -$3.28 B | -$3.39 B |
| EBITDA Margin (%) |
|
-266.68% | 76.27% | 50.71% | -47.94% | -104.88% |
Moderna Ratios
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
-29.17% | 86.26% | 43.73% | -34.03% | -32.67% |
| Return on Assets (ROA) |
|
-10.18% | 49.46% | 32.34% | -25.58% | -25.18% |
| Debt to Equity |
|
- | - | - | 8.97% | 6.51% |
| Debt to total asset |
|
- | - | - | 6.75% | 5.02% |
| Enterprise value to revenue |
|
135.57 | 5.38 | 3.51 | 5.30 | 4.56 |
| Enterprise value to EBITDA |
|
-50.84 | 7.06 | 6.92 | -11.06 | -4.35 |
| Enterprise value |
|
$37.21 B | $95.51 B | $67.57 B | $36.33 B | $14.75 B |
| Cash to Debt |
|
- | - | - | -250.84% | -423.10% |
| Tax Rate (%) |
|
-0.34% | 8.15% | 12.67% | -19.58% | 1.28% |
| Payout Ratio |
|
- | - | - | - | - |
